ArticleInfection and drug resistance2024
Clinical Characteristics of
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Rapid diagnosis ofExperimental and therapeutic medicine · 2026Article
- Clinical characteristics and prognosis of patients with Chlamydia psittaci pneumonia identified by metagenomic next-generation sequencing.BMC infectious diseases · 2026Article
- Antimicrobial Management of SevereInfection and drug resistance · 2026Review
- Clinical Features of 186 Cases ofInfection and drug resistance · 2026Article
- Systemic inflammation, multi-organ injury, and acute kidney risk in psittacosis pneumonia: a biomarker-driven clinical characterization.Frontiers in cellular and infection microbiology · 2026Article
- Clinical characteristics and risk factors associated with severe community-acquired pneumonia infected byMicrobiology spectrum · 2025Article
- Article
- A Case of Psittacosis - Putian City, Fujian Province, China, April 2025.China CDC weekly · 2025Article
- Liver Function Abnormalities in Patients withInfection and drug resistance · 2025Article
- Epidemiological features and risk factors of human psittacosis in Hangzhou City, eastern China.Frontiers in public health · 2025Article
- Clinical Characteristics and Predicting Disease Severity in Chlamydia psittaci Infection Based on Metagenomic Next-Generation Sequencing.Infection and drug resistance · 2025Article
- Epidemiological characteristics of human psittacosis in Guangzhou, China, January 2021 to June 2024.Frontiers in public health · 2025Article
- Psittacosis chlamydia pneumonia complicated with organizing pneumonia: a case report and literature review.Frontiers in medicine · 2025Article
- Effectiveness of Omadacycline in a Patient withInfection and drug resistance · 2025Article
- Acute respiratory distress syndrome caused byFrontiers in medicine · 2024Article
- Analysis and Perception ofInfection and drug resistance · 2024Article
- Early and rapid diagnosis ofFrontiers in medicine · 2024Article
- Clinical characteristics and outcomes of Chlamydia psittaci pneumonia: Insights from targeted next-generation sequencing diagnosis.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to describe and compare the epidemiological, demographic, clinical, laboratory and radiological characteristics as well as the complications, treatments, and outcomes of these patients. Methods: We retrospectively investigated clinical data of patients with Results: A total of 74 patients (39 severe/35 non-severe) was diagnosed with psittacosis, 25 (33.8%) of whom had history of poultry exposure. Common symptoms included high fever (98% [37/74]), fatigue (52.7% [39/74]), and dyspnea (51.4% [38/74]). Common manifestations in imaging included consolidation (89.2%), pleural effusion (77.0%), and air bronchogram (66.2%). Common complications included acute respiratory distress syndrome (55.4% [41/74]), type I respiratory failure (52.7% [39/74]), acute liver injury (41.9% [31/74]), and secondary infection (27.0% [20/74]). The in-hospital mortality rate was 8.11% (6/74). Conclusion: C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.